Fresenius Group Overview

  • Q1-3 & Q3 2018 Results

    Fresenius in Q3/18 with continued strong Group earnings growth in constant currency

New Developments

Financial Highlights

Sales

€ 8192 m

+4%1, 2

Q3/2017: €7,927 m1

EBITDA3

€ 1463 m

0%2, 4

Q3/2017: €1,481 m

EBIT3

€ 1112 m

0%2, 4

Q3/2017: €1,129 m

Employees

277,318

Dec. 31, 2017: 273,249

Net Income3

€ 445 m

+8%2, 4

Q3/2017: €413 m

Earnings per Share3

€ 0.80

+7%2, 4

Q3/2017: €0.75

1 Adjusted for IFRS 15 adoption and divestitures of Care Coordination activities
2 In constant currency
3 Before special items
4 Before divestitures of Care Coordination activities

CEO message

“In the third quarter, Fresenius again achieved healthy sales growth and drove earnings growth even a touch stronger. Fresenius Kabi, Fresenius Vamed and Quirónsalud delivered a truly excellent performance. At the same time, Fresenius Medical Care and our German Helios hospitals will enhance their efforts to further improve and adapt to changing market conditions. From an overall position of strength, we are in the closing stretch for yet another record year.”

 

 


Stephan Sturm, Chairman of the Management Board 

  • Business Segments

    • 3% comparable sales growth in constant currency in Q3
    • -2% adjusted net income decrease in constant currency in Q3
    • Outlook for FY/18 adjusted

     

  • Business Segments

    • 8% organic sales growth and 14% EBIT growth in constant currency (excl. biosimilars expenses) in Q3
    • Sales outlook confirmed and strengthened: top end of 4% to 7% organic sales growth expected
    • EBIT outlook raised: 1% to 3%  EBIT growth in constant currency expected (~9% to 11%  excl. biosimilars expenses)

  • Business Segments

    • 2% organic sales growth in Q3
    • Preparatory initiatives for expected regulatory requirements and decline in admissions impact financial performance of Helios Germany
    • Helios Spain with steady yet dynamic growth
    • 2018 sales outlook confirmed and narrowed, EBIT outlook adjusted: 0% to 2% (previously: 5% to 8%)

  • Business Segments

    • Excellent organic sales growth of 30% in Q3/18
    • Both service and project businesses contributed to strong growth in Q3/18
    • FY/18 outlook confirmed

     

     

     

News

All Financial Reports